Growth offset by acquisition drag; transformation in motion

Revenue ₹8,017 Cr, +22% YoY; management cited 22% vs FY26, exceeding high-teens guidance

Delivered OPM 23.8%; calculated EBITDA ₹1,930 Cr ÷ ₹8,017 Cr = 24.1%. On-track vs 24%+ FY27 guidance.

PAT ₹990.2 Cr, down 34.9% YoY; driven by acquisition amortization (Assertio, Zylidac), Mirabegron royalty costs, depreciation spike. Management did not proactively flag severity.

India formulations +20%, International formulations +34%, Consumer +67%, but North America only +5% QoQ due to Mirabegron exclusivity expiry impact.

Q1 India formulations +20% YoY, better than prior 300-500 bps guidance. Chronic portfolio at 54.2%, innovation/biosimilar strong. Management reaffirmed mid-teens sustainability.

Despite Q1 beat at 24.1%, management maintained 24% FY27 guidance. Did not upgrade despite strong India momentum, signaling expected margin pressure from Saro ramp, acquisitions, and R&D investment in 2H.

Management reiterated 2/3 branded revenue target over medium term (was 55% in Q1). Implies ₹300–400 Cr shift from generics to branded business. Supported by chronic portfolio at 54.2% (up 360 bps in 4 years) and innovation scaling.

Assertio acquisition completed with Rolvedon biosimilar. US branded now 10% of US revenue; management targets 15%+ by year-end. Specialty stack now includes Sentynl ($60M ultra-rare), 505(b)(2) cluster ($60–70M), Rolvedon ($15–20M/qtr ramp).

Management observes peer guidance upgrades in PBC market (larger patient pool than previously estimated). Conservative peak sales $200–300M, optimistic $400M+. Expanded indication trial (marginal ALP) about to start, adding upside optionality.

Zydus Biotech Park received EIR with VAI (Voluntary Action Indicated) in April–May 2026 GMP surveillance. No detail on remediation timeline; could delay future capacity expansion or new approvals.

No, sticking with strong double-digit guidance. India mid-teens, US single-digit. Q1 benefited from exceptional biosimilar/innovation uptake and chronic growth; not all will repeat evenly across quarters.

Assertio amortization not yet in Q1 P&L (12-month allocation window). Saro costs ramping H2 FY27, but still guiding 24%+ margin; run-rate other expenses ₹1,900–₹2,000 Cr/quarter inclusive.

₹1,500–₹1,600 Cr FY27 guidance. Spend on SEZ-3, Moraiya/Goa/Baddi expansion, new R&D center, CAR-T facility, vaccine DS facility, wellness land acquisition (one-time). Multiple items, no single large driver besides wellness land.

Building for FY28 April launch. First 2 years investment phase; no meaningful revenue year 1. Conservative peak $200–300M, optimistic $400M+. Market feedback from peers suggests bigger patient pool. Expanded indication (marginal ALP trial) starting, adds 2–3 year optionality.

Q1 10% branded excludes Assertio (not yet in numbers). Sentynl ultra-rare ~$60M (LY). Remaining ~$60–70M from 505(b)(2) cluster. Assertio ramps from Q2 FY27 at $15–20M/qtr. Branded share will reach 15%+ by year-end.

Three drivers: (1) Chronic portfolio growing >20%, strong AWACS July momentum. (2) Saro/Desi uptick 30–45% growth, scaling well. (3) Biosimilars 3–4 brands post-genericization strong. Semaglutide is small contributor, third-largest in market share but small overall. Differentiated pipeline and chronic business sustain mid-teens growth.

Three things: (1) Core existing emerging markets doing better than LY, strong growth. (2) Europe (France, Spain, UK) transformed; old markets now strong, UK scaled faster than expected. (3) New geographies seeing innovation/first-generic launches with good traction. All three supporting sustained growth.

19 in-house, 8 partnered. 4+ commercialized, most doing better than expected. BEIZRAY slower than plan, hope for bigger ramp in FY28. Other 2–3 products strong. Rolvedon ramping meaningfully. Ranibizumab (Nufymco) + PFS next year good uptick. Sentynl rare disease doing well. Portfolio growing well.

Mirabegron settlement arrangement with innovator incurs higher costs Q1. Quarterly hit from this. But Mirabegron still semi-exclusive, very profitable. Not a negative; positive side of story. Full-year 24% EBITDA guidance factors this in.

FY28 launch. First 2 years build-out phase for investment; no significant revenue year 1. Year 2–3 ramp. Can give better color in last quarter near launch. Investment costs ramping H2 FY27 and all of FY28.

Semaglutide is sustainable momentum, but our 20% growth NOT factored around Sema. It's a small contributor. Growth has come from other products (chronic, biosimilar, innovation). Don't over-index on Sema.

We're investing on both generic and branded side. Better profile vs this year coming. Pipeline strong, will see improvement.

First couple years investment phase on Saro and other portfolio, R&D increase. Ideally want to improve to 28–30% range as move closer to 5-year period.

Q1 delivered 22% growth with India at 20%. Guidance reaffirmed by management; mid-teens India is lower than 22% base, suggesting possible H2 normalization or mix shift.

Mirabegron exclusivity erosion dragging. However, specialty ramp (Assertio, Nufymco, 505(b)(2)) and Saro pre-launch could offset in H2. Confidence medium due to competitive intensity and ramp dependencies.

Q1 at 24.1%, on-track. Management holding firm despite capex spike, acquisition amortization, Saro investment. Confidence high for 24% maintenance this year; 28–30% by FY30 contingent on branded mix shift (2/3) and Saro ramp success.

Multiple projects identified. Sustainability of spend post-FY27 not detailed; likely normalizes once facilities ready. Confidence high for FY27 number delivery.

PAT down 34.9% YoY despite 22% revenue growth due to acquisition-related amortization (Assertio, Zylidac, Mirabegron settlement), increased D&A, and Saro pre-launch costs. This burden continues through FY28. Management expects margin recovery post-FY28 if Saro scales and branded mix improves, but near-term profitability pressure is real.

Saro is flagship specialty asset for US with FY28 launch expected. First 2 years are investment phase with minimal revenue. Peak sales estimates range $200–300M (conservative) to $400M+ (optimistic)—a 100%+ spread indicating uncertainty. FDA priority review granted for PBC, but expanded indication (marginal ALP) will take 2–3 years. If market is smaller than $200M or ramp delays, Saro ROI will be materially impaired.

North America revenues only +5% QoQ despite global momentum, due to Mirabegron semi-exclusive status erosion. Single-digit FY27 growth guidance already reflects this headwind. Further generics competition, new entrants in Mirabegron, or faster-than-expected loss of pricing power could cause US segment to stall or decline. Specialty ramp (Assertio, Nufymco, 505(b)(2)) may not fully offset.

FY27 capex guidance of ₹1,500–₹1,600 Cr is 2x historical run-rate (~₹700–800 Cr). Covers SEZ-3 completion, facility expansions (Moraiya, Goa, Baddi, Unit-2/3 SEZ), new R&D center, CAR-T facility, vaccine DS facility, wellness land. High capex combined with acquisition debt and Saro investment spend could constrain dividend or FCF generation in near term.

Zydus Biotech Park injectable facility received Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification following GMP surveillance in April–May 2026. VAI indicates non-compliance requiring corrective action but no warning letter yet. Remediation timeline not disclosed. If resolution is slow or requires significant reinvestment, facility capacity plans and injectable product approvals/transfers could be delayed.